Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 9, 2003, Pages 951-957

  Muriel, Pablo ^a,b   Fernández Martínez, Eduardo ^a   Pérez Álvarez, Víctor ^a   Lara Ochoa, Francisco ^c   Ponce, Susana ^a   García, Julio ^a   Shibayama, Mineko ^b   Tsutsumi, Víctor ^b  

^a Secc de Farmacología   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c Instituto de Quimica de la UNAM   (Mexico)

Author keywords

Cirrhosis; Collagen; Fibrosis; Inflammation; Necrosis; Thalidomide

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CARBON TETRACHLORIDE; GAMMA GLUTAMYLTRANSFERASE; THALIDOMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTOXICATION; LIPID PEROXIDATION; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; CARBON TETRACHLORIDE; DRUG EVALUATION, PRECLINICAL; GAMMA-GLUTAMYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; RATS; RATS, WISTAR; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 0042762666     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200309000-00003     Document Type: Article

References (33)

1. Marriot JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999; 20:538-540.
2. Miller MT, Strömland K. Teratogen update: thalidomide: a review, with focus on ocular findings and new potential uses. Teratology 1999; 60:306-321.
3. Lenz W. A short history of thalidomide embryopathy. Teratology 1988; 38:203-215.
4. Eriksson T, Björkmann S, Höglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001; 57:365-326.
5. Raje N, Anderson K. Thalidomide: a revival story. N Engl J Med 1999; 341:1606-1608.
6. Fernández-Martínez E, Morales-Ríos MS, Pérez-Alvarez V, Muriel P. Effects of thalidomide and 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanamide on bile duct obstruction-induced cirrhosis in the rat. Drug Dev Res 2001; 54:209-218.
7. Moncada B, Baranda ML, Gonzalez-Amaro R, Urbina R, Loredo CE. Thalidomide - effect on T cell subsets as a possible mechanism of action. Int J Lepr 1985; 53:201-205.
8. Vogelsang GB, Hess AD, Gordon G, Santos GW. Treatment and prevention of acute graff-versus-host disease with thalidomide in a rat model. Transplantation 1986; 41:644-647.
9. Neubert D, Köhler E. Hypothetical explanation of the embryotoxic action of thalidomide. Arch Pharmacol 1970; 266:408-409.
10. Flohé L, Draeger E, Frankus E, Graudums I, Günsler WA, Helm FC, et al. Studies on the hypothetical relationship of thalidomide-induced embryopathy and collagen biosynthesis. Arzneim Forsch 1981; 31:315-320.
11. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177:1675-1680.
12. Muriel P. Nitric oxide protection of rat liver from lipid peroxidation, collagen accumulation, and liver damage induced by carbon tetrachloride. Biochem Pharmacol 1998; 56:773-779.
13. Bradham CA, Plümpe J, Manns MP, Brenner DA, Trautwein C. Mechanisms of hepatic toxicity I. TNF-induced liver injury. Am J Physiol 1998; 278:G387-G392.
14. Bergmeyer HU, Grabl M, Walter HE. Enzymes. In: Bergmeyer J, Grabl M, editors. Methods of Enzymatic Analysis. Weinheim: Verlag-Chemie; 1983. pp. 269-270.
15. Reitman S, Frankel S. A colorimetric method for determination of serum oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28:56-63.
16. Glossman M, Neville DM. Glutamyl transferase in kidney brush border membranes. FEBS Lett 1972; 19:340-344.
17. Okawa H, Ohmishi N, Yagi K. Assay for lipid peroxides in animal tissues by the thiobarbituric acid reaction. Anal Biochem 1979; 98:351-358.
18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976; 72:248-254.
19. Seifter S, Dayton S, Novic B, Muntwyler E. The estimation of glycogen with the anthrone reagent. Arch Biochem 1950; 28:191-200.
20. Prockop DJ, Udenfriend S. A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem 1960; 1:228-239.
21. Zar JH. Biostatistical Analysis. Englewood Cliffs NJ: Prentice-Hall; 1984.
22. Kaplan MM. Serum alkaline phosphatase, another piece is added to the puzzle. Hepatology 1986; 6:226-228.
23. Kaplan MM. Laboratory test. In: Shift L, Shift ER, editors. Diseases of the Liver. Philadelphia: Lippincott Company; 1993. pp. 108-144.
24. Bulle F, Mavier P, Zafrani ES, Preaux AM, Lescs MC, Siegrist S, et al. Mechanism of gamma-glutamyl transpeptidase release in serum during intrahepatic and extrahepatic cholestasis in the rat. A histochemical, biochemical and molecular approach. Hepatology 1990; 11:545-550.
25. Muriel P. Peroxidation of lipids and liver damage. In: Baskin S, Salem H, editors. Oxidants, Antioxidants, and Free Radicals. Washington: Taylor & Francis; 1997. pp. 237-257.
26. Somers GF. Pharmacological properties of thalidomide (α -phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol 1960; 15:111-116.
27. Koch HP. Thalidomide and congeners as anti-inflammatory agents. Prog Med Chem 1985; 22:166-242.
28. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, et al. Thalidomide for the treatment of graft-versus-host disease. N Engl J Med 1992; 326:1055-1058.
29. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatol 1998; 25:964-969.
30. Mchugh SM, Rifkin IR, Deighton J, Wilson AB, Lachman PJ, Lockwood CM, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99:160-167.
31. Muriel P, Alba N, Pérez-Álvarez VM, Shibayama M, Tsutsumi VK. Kupffer cell inhibition prevents hepatic lipid peroxidation and damage induced by carbon tetrachloride. Comp Biochem Physiol C 2001; 130:219-226.
32. Muriel P, Escobar Y. Kupffer cells are responsible for liver cirrhosis induced by carbon tetrachloride. J Appl Toxicol 2003; 23:103-108.
33. Hanauske-Abel H, Gunzler V. Inhibition of human prolyl hydroxylase as common biochemical denominator of the non-sedative effects of thalidomide in man. Z Naturfosch 1977; 32:241-248.